Glenmark faces patent infringement suit for cancer drug in US

Glenmark Pharmaceuticals has been slapped with a patent infringement case by US-based Cephalon Inc

RELATED ARTICLES

over plans to sell generic version of leukaemia treatment drug Treanda in the American market.

"Glenmark Pharmaceuticals Ltd and Glenmark Generics Inc, USA '(Glenmark') confirms Cephalon Inc has filed a patent infringement suit on 26 Dec 2013 in the US District Court for the District of Delaware seeking to prevent Glenmark from commercialising its Abbreviated New Drug Application (ANDA) for Bendamustine Hydrochloride product," the company said.

The complaint has been filed against Glenmark trying to commercialise the product before the expiry of patent which is a generic version of Treanda, it added.

"A complaint against Glenmark has been filed on US patent 8,445,524," Glenmark said.

Bendamustine is indicated for the treatment of patients with chronic lymphocytic leukemia, it added.

Shares of Glenmark Pharmaceuticals were today trading at Rs 533 per scrip in the early afternoon on BSE, up 0.18 per cent, from its previous close.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • Amit Shah deserved to be crowned President of India, some say

    The Bharatiya Janata Party is now firmly in the hands of Modi’s alter ego, which in plain English means ‘another side of oneself, a second self’

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Arun Nigavekar

Necessary yet inadequate boost to education

The finance minister, in the very first minutes of his ...

Zehra Naqvi

We must overcome the fear of death

It is the biggest irony that the only thing that’s ...

Dharmendra Khandal

Jawai leopards and locals can coexist peacefully

At first glance, the Jawai landscape seems like a large ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture